From Genes to Drugs: Integrating Genomics, Proteomics and Bioinformatics
	SMi , The Hatton, London 3rd & 4th April 2000
	Day One – 3rd April 2000 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Dr Neil MacKenzie, Business Development Director, Oxford Biomedica FROM GENES TO DRUGS 9.10 From sequence through structure to function Dr Mark Swindells, Chief Scientific Officer, Inpharmatica BOTTLENECKS IN DRUG DISCOVERY AND DEVELOPMENT 9.40 Using genomics to widen the bottlenecks in drug discovery Dr Patrick Kleyn, Chief Scientific Officer, Gemini Research THE USE OF FUNCTIONAL GENOMICS AS A RESEARCH TOOL 10.20 Functional genomics and drug discovery Dr Hartmut Voss, Vice President Genomics, LION Biosciences 11.00 Morning coffee GENE EXPRESSION PROFILING 11.20 Case study: GlaxoWellcome Dr Edward Zanders, Senior Scientist, GlaxoWellcome SPEEDING UP TOXICITY TESTING 12.00 Case study: Hoffman-La Roche and microarrays Dr Jan Mous, Global Head of Genomic Technology, Hoffmann-La Roche 12.40 Lunch FROM GENOMICS TO THERAPEUTICS 2.00 The use of industrialised phage antibody technology Dr Kevin Pritchard, Head of Protein Chemistry, Cambridge Antibody Technology INTEGRATING PROTEOMICS AND GENOMICS 2.40 Case study: Incyte and Oxford GlycoSciences Dr Mark Egerton, Vice President, Incyte 3.20 Afternoon Tea HUMAN PHENOMICS IN DRUG DISCOVERY 3.40 Case study: Pharmagene Dr Alastair Riddell, Chief Executive Officer, Pharmagene TECHNOLOGY TRANSFER IN BIOTECHNOLOGY 4.20 Acquiring the right technology and ensuring the interests of both parties Dr George Rahim, Technical Manager, MMI 5.00 Chairman’s Closing Remarks and Close of Day One 5.10 Drinks Reception Day Two – 4th April 2000 9.00 Chairman's Opening Remarks Dr Richard Judson, Vice President Bioinformatics, Gennaissance PHARMACOGENOMICS AND CLINICAL TRIALS 9.10 Will pharmacogenomics speed up drug development? Dr Fred Ledley, Principle Scientific Advisor, Variagenics GENOTYPING IN ALZHEIMER’S DISEASE 9.40 Case study: Eli Lilly and Xanomeline Dr Larry Altstiel, Group Leader Neurodegenerative Disorders, Eli Lilly IMPROVING THE ACCESSIBILITY OF BIOINFORMATICS 10.20 Providing the right user interface to enable effective use of bioinformatics Eli Mintz, President, Compugen 11.00 Morning Coffee EFFECTIVE USE OF BIOINFORMATICS 11.20 The role of bioinformatics in drug discovery and development Christophe Person, Director of Informatics, Lexicon Genetics INTEGRATING DISCOVERY INFORMATICS 12.00 The value of an integration strategy and integration solutions Manuel Glynias, President & Chief Executive Officer, NetGenics 12.40 Lunch DATAMINING TO IDENTIFY NOVEL TARGETS 2.00 Case study: Johnson & Johnson Dr Michael Jackson, Senior Director, The R. W. Johnson Pharmaceutical Research Institute BIOINFORMATICS AND DEVELOPMENT OF PROTEIN THERAPEUTICS 2.40 Case study: Novo Nordisk Dr Henrik Vissing, Head of Bioinformatics & Genomics, Novo Nordisk 3.20 Afternoon Tea IDENTIFICATION OF NEW ANTI-FUNGALS 3.40 Case study: Scriptgen and effective integration of bioinformatics and genomics Dr Richard Wobbe, Senior Director Drug Discovery, Scriptgen IDENTIFICATION OF LEAD COMPOUNDS 4.20 Case study: ACADIA Pharmaceuticals and the hunt for muscarinic ligands Dr Mark Brann, President & Chief Scientific Officer, ACADIA Pharmaceuticals 5.00 Chairman's Closing Remarks and Close of Conference
	Organized by:	SMi
	Invited Speakers:	Dr Jan Mous, Global Head of Genomic Technology, Hoffmann-La Roche Dr Hatmut voss, Vice President Genomics, LION biosciences Dr Mark Egerton, Vice President, Incyte Dr Larry Altstiel, Group Leader Neurodegernerative Disorders, Eli Lilly Dr Michael Jackson, Senior Director, The R. W. Johnson Pharmaceutical Research Institute Dr Henrik Vissing, Head of BIoinformatics & Genomics, Novo Nordisk Dr Edward Zanders,Senior Scientist, GlaxoWellcome, Dr Patrick Kelyn, Cheif Scientific Officer, Gemini Research
	Deadline for Abstracts:	Passed
	Registration:	Go to web site
	Email for Requests and Registration:	swatt@smiconferences.co.uk
	Posted by: Suzanne Watt   Host: 193.128.16.129 date: March 07, 2000 10:25:43 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.